HBIO
Harvard Bioscience Inc
NASDAQ: HBIO · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$6.12
+3.38% today
Updated 2026-07-29
Market cap
$27.06M
P/E ratio
—
P/S ratio
0.32x
EPS (TTM)
$-2.15
Dividend yield
—
52W range
$4 – $9
Volume
0.0M
Harvard Bioscience Inc (HBIO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$6.12
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -11.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.